Clinical Trial Update: Atomoxetine Treatment for Cognitive Impairment in Parkinson's Disease (ATM-Cog) [Phase 2]

View source ↗

Summary

Phase 2 trial update for atomoxetine in cognitive impairment associated with Parkinson's disease has completed with results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cognitive Impairment
• Parkinson Disease

Drugs mentioned

• Atomoxetine (Atomoxetine)

Snippet

Sponsor: Medical University of South Carolina | Conditions: Parkinson's Disease, Cognitive Impairment | Phase 2 | Status: COMPLETED | Results posted: 2018-08-23